Talphera, Inc. (NASDAQ:TLPH) Short Interest Update

Talphera, Inc. (NASDAQ:TLPH) was the recipient of a large drop in short interest during the month of October. As of October 15th, there was short interest totalling 34,300 shares, a drop of 18.9% from the September 30th total of 42,300 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average daily volume of 95,400 shares, the days-to-cover ratio is currently 0.4 days.

Talphera Stock Performance

Shares of TLPH stock opened at $0.97 on Monday. Talphera has a fifty-two week low of $0.43 and a fifty-two week high of $1.61. The stock’s 50-day simple moving average is $0.91 and its 200-day simple moving average is $0.95. The firm has a market capitalization of $16.54 million, a PE ratio of -1.09 and a beta of 0.32.

Talphera (NASDAQ:TLPH) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.07. Sell-side analysts forecast that Talphera will post -0.73 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Talphera in a research report on Friday, August 16th.

Hedge Funds Weigh In On Talphera

A hedge fund recently bought a new stake in Talphera stock. Nantahala Capital Management LLC bought a new stake in shares of Talphera, Inc. (NASDAQ:TLPH) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,992,519 shares of the company’s stock, valued at approximately $1,773,000. Nantahala Capital Management LLC owned 11.73% of Talphera as of its most recent SEC filing. Institutional investors own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.